NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001732

Registered date:23/02/2009

Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the partients who have received trans-arterial infusion chemotherapy against advanced hepatocellular carcinoma -A randomized double blind study-

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedhepatocellular carcinoma
Date of first enrollment2009/02/01
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Cancer vaccination therapy by using tumor-associated antigen GPC3-targeted peptide in the patients who have received trans-arterial infusion chemotherapy against advanced HCCs. Cancer vaccination therapy by using IFA in the patients who have received trans-arterial infusion chemotherapy against advanced HCCs.

Outcome(s)

Primary Outcomesafety
Secondary Outcomeimmunologicalresponse and clinical efficacy

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients judged inappropriated by doctors.

Related Information

Contact

public contact
Name
Address 1-1-1 Honjo, Kumamoto city, Kumamoto 860-8556, Japan Japan
Telephone 096-373-5150
E-mail
Affiliation Graduate School of Medical Sciences Kumamoto University Department of Gastroenterology and Hepatology
scientific contact
Name Yutaka Sasaki
Address 1-1-1 Honjo, Kumamoto city, Kumamoto 860-8556, Japan Japan
Telephone 096-373-5150
E-mail
Affiliation Graduate School of Medical Sciences Kumamoto University Department of Gastroenterology and Hepatology